This content is in French.
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL CONGRESS ESMO 2020
19 Septembre 2020 · 3 joursOnline, SpainOncologyEnglish
OnlineAbout this congress
The ESMO Congress 2020 will take place from 18 to 22 September 2020, at the IFEMA – Feria de Madrid, Spain.The ESMO Congress is the most influential oncology platform in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world. ESMO Congress 2020 will present the very latest advances in oncology and translate science into better cancer patient care.The ESMO Congress 2020 programme will be developed by a committee composed of more than 300 international experts under the leadership of Scientific Chair Prof John Haanen, NKI Amsterdam, Netherlands, a leading expert in the field of immunotherapy.ESMO invites all oncology stakeholders: researchers, clinicians, industry partners, patient advocates and members of the press to mark their calendars for ESMO Congress 2020 in Madrid.
Videos from this congress
Play the video · OncLive News Network On Location: ESMO 2020 Day 3Free registration required to play
00:44:29
Play the video · OncLive News Network On Location: ESMO 2020 Day 1Free registration required to play
00:38:53
Play the video · Philip Jerman · ESMO 2020 Satellite Symposium: Philip Jermann - NTRK, RET and other fusion biomarkers testingFree registration required to play
Philip Jerman · 00:12:53
Play the video · Christophe Borg · ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 studyFree registration required to play
Christophe Borg · 00:02:44
Play the video · Ajjai Alva · ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 studyFree registration required to play
Ajjai Alva · 00:03:20
Play the video · David Hong · ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLCFree registration required to play
David Hong · 00:03:03
Play the video · Daniel Renouf · ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 studyFree registration required to play
Daniel Renouf · 00:03:54
Play the video · Toni Choueiri · ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER studyFree registration required to play
Toni Choueiri · 00:02:04
Play the video · Solange Peters · ESMO Virtual Congress 2020Free registration required to play
Solange Peters · 00:01:55
Play the video · ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancersFree registration required to play
00:04:52
Play the video · Johann de Bono · ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 studyFree registration required to play
Johann de Bono · 00:03:06
Play the video · Zarnie Lwin · ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005Free registration required to play
Zarnie Lwin · 00:02:56